1/12/06

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10810649-2.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:40:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1731 TO ITERATE

100.0% PROCESSED 1731 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.05

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 32125 TO 37115
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

10810649

```
=> s l1 ful
FULL SEARCH INITIATED 14:41:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    34394 TO ITERATE

100.0% PROCESSED    34394 ITERATIONS                                 3 ANSWERS
SEARCH TIME: 00.00.01

L3            3 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   166.94     167.15

FILE 'CAPLUS' ENTERED AT 14:41:09 ON 12 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 12 Jan 2006  VOL 144 ISS 3
FILE LAST UPDATED: 11 Jan 2006  (20060111/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4            2 L3

=> d abs fbib hitstr 1-2

L4   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
GI
```



I



II

AB Novel polyamines, their synthesis and use in pharmacol., cosmetic or agricultural applications are provided. Novel polyamines having the structure (I) [wherein, n = 0-8; the aminomethyl functionality can be ortho, meta or para substituted; R = H, Me, Et, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminooctyl, N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminooctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl, N-ethyl-8-aminooctyl; R1 = H, straight or branched C1-20 (un)saturated aliphatic, aliphatic amine (except for propylamine when R = H, n=1 and the aminomethyl functionality is para substituted), alicyclic group, single or multi-ring aromatic group, single or multi-ring aryl substituted aliphatic group, aliphatic-substituted single or multi-ring aromatic group, single or multi-ring heterocyclyl, single or multi-ring heterocyclic-substituted aliphatic, aliphatic-substituted aromatic group, halogenated forms thereof; wherein said polyamine is a non-sym. xylene] are prepared Also provided are the use of the polyamines in pharmacol., cosmetic or agricultural applications. The polyamines induce antizyme production which in turn down regulates both the production of polyamines by ornithine decarboxylase (ODC) and the transport of polyamines by its corresponding polyamine transporter. These compds. will preferably enter the cell independent of the polyamine transporter. As drugs, these compds. are used as fungal, bacterial, viral and parasitic agents or to treat any disease associated with cellular proliferation including cancer, mucositis, asthma, inflammation, autoimmune disease, psoriasis, restentosis, rheumatoid arthritis, scleroderma, systemic and cutaneous lupus erythematosus, Type I insulin dependent diabetes, tissue transplantation, osteoporosis, hyperparathyroidism, treatment of peptic ulcer, glaucoma, Alzheimer's disease, Crohn's disease, and other inflammatory bowel diseases. A series of compds. I were screened for their ability to induce frameshifting using the dual luciferase reporter assay in HEK-293 cells. Some of these compds. induced frameshifting substantially better than spermidine. For example, compound (II) showed the percent relative frameshifting value (% RF) of 150% compared to 25 μM spermidine.

AN 2004:878166 CAPLUS
DN 141:366226
TI Preparation of polyamine analogs that activate antizyme frameshifting
IN Burns, Mark R.; Graminski, Gerard F.
PA Mediquest Therapeutics, Inc., USA
SO U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 251,819.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004209926	A1	20041021	US 2004-810649	20040329
				US 2002-251819 A2	20020923
	US 2004058954	A1	20040325	US 2002-251819	20020923
	US 6914079	B2	20050705		

PATENT FAMILY INFORMATION:
FAN 2004:252193

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004058954	A1	20040325	US 2002-251819	20020923

US 6914079 B2 20050705
US 2004209926 A1 20041021 US 2004-810649 20040329
US 2002-251819 A2 20020923
WO 2005105729 A1 20051110 WO 2004-US9582 20040329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2002-251819 A 20020923

OS MARPAT 141:366226

IT **673461-33-1P**, 1-Aminomethyl-4-(10-amino-2,7-diazadecyl)benzene
778831-92-8P, 1-Aminomethyl-4-(11-amino-2,7-diazaundecyl)benzene
778831-98-4P, 1-Aminomethyl-4-(12-amino-2,7-diazadodecyl)benzene
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of polyamine analogs as activating agents for antizyme frameshifting to treat diseases associated with cellular proliferation or as antifungal, antibacterial, antiviral and antiparasitic agents)

RN 673461-33-1 CAPLUS
CN 1,4-Benzenedimethanamine, N-[4-[(3-aminopropyl)amino]butyl]- (9CI) (CA INDEX NAME)



RN 778831-92-8 CAPLUS
CN 1,4-Benzenedimethanamine, N-[4-[(4-aminobutyl)amino]butyl]- (9CI) (CA INDEX NAME)



RN 778831-98-4 CAPLUS
CN 1,4-Benzenedimethanamine, N-[4-[(5-aminopentyl)amino]butyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

AB The invention provides synthesis and use of polyamines in pharmacol., cosmetic or agricultural applications. The polyamines induce antizyme production which in turn down regulates both the production of polyamines by ornithine decarboxylase (ODC) and the transport of polyamines by its corresponding polyamine transporter. These compds. will preferably enter the cell independent of the polyamine transporter. As drugs, these compds. are used to treat any disease associated with cellular proliferation including but not limited to cancer. As such, they will be useful as drugs to treat diseases where components of the immune system undergo undesired proliferation. The compds. will also be effective for the treatment of unwanted proliferation of hair or skin. The invention also identifies key structural elements expected to comprise the antizyme inducing motifs of small mols. related to polyamines.

AN 2004:252193 CAPLUS

DN 140:264534

TI Polyamine analogs that activate antizyme framshifting

IN Burns, Mark R.; Graminski, Gerard F.

PA Mediquest Therapeutics, Inc., USA

SO U.S. Pat. Appl. Publ., 29 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004058954	A1	20040325	US 2002-251819	20020923
	US 6914079	B2	20050705		
	US 2004209926	A1	20041021	US 2004-810649	20040329
				US 2002-251819 A2	20020923
	WO 2005105729	A1	20051110	WO 2004-US9582	20040329

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002-251819 A 20020923

PATENT FAMILY INFORMATION:

FAN 2004:878166

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004209926	A1	20041021	US 2004-810649	20040329
				US 2002-251819 A2	20020923
	US 2004058954	A1	20040325	US 2002-251819	20020923
	US 6914079	B2	20050705		

1/12/06

OS MARPAT 140:264534
IT **673461-33-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polyamine analogs that activate antizyme framshifting)
RN 673461-33-1 CAPLUS
CN 1,4-Benzenedimethanamine, N-[4-[(3-aminopropyl)amino]butyl]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

1/12/06

CT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10810649-3.str



chain nodes :
7 8 9 10 11 12 18 19 20 21 22 23 24 25 26 27
ring nodes :
1 2 3 4 5 6
chain bonds :
1-9 2-23 3-22 4-7 5-21 6-20 7-8 7-18 7-19 9-10 10-27 11-12 11-24 24-26 24-25 24-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-8 24-26
exact bonds :
1-9 2-23 3-22 4-7 5-21 6-20 7-18 7-19 9-10 10-27 11-12 11-24 24-25 24-27

10810649

```
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS  18:CLASS  19:CLASS  20:CLASS  21:CLASS  22:CLASS  23:CLASS
24:CLASS  25:CLASS
26:CLASS  27:CLASS



L6      STRUCTURE UPLOADED

=> s l6
SAMPLE SEARCH INITIATED 17:25:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    53297 TO ITERATE

  3.8% PROCESSED     2000 ITERATIONS                                  0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      1052176 TO  1079704
PROJECTED ANSWERS:               0 TO        0

L7            0 SEA SSS SAM L6

=> s l6 ful
FULL SEARCH INITIATED 17:25:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  1053005 TO ITERATE

 95.0% PROCESSED  1000000 ITERATIONS                                 5 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.04

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      1053005 TO  1053005
PROJECTED ANSWERS:               5 TO       11

L8            5 SEA SSS FUL L6

=> d scan

L8   5 ANSWERS   REGISTRY  COPYRIGHT 2006 ACS on STN
IN   1,4-Benzenedimethanamine, N-(3-aminopropyl)- (9CI)
MF   C11 H19 N3
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2-5
'2-5' IS NOT VALID HERE

To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L8 5 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenemethanamine, 2,5-difluoro-4-hydrazino- (9CI)
MF C7 H9 F2 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 5 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenemethanamine, 3-chloro-4-hydrazino- (9CI)
MF C7 H10 Cl N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 5 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenemethanamine, 4-hydrazino-3-nitro- (9CI)
MF C7 H10 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 5 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenemethanamine, 4-hydrazino-3-(trifluoromethyl)- (9CI)
MF C8 H10 F3 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>
Uploading C:\Program Files\Stnexp\Queries\10810649-3.str



chain nodes :
7 8 9 10 11 12 18 19 20 21 22 23 24 25 26 27
ring nodes :
1 2 3 4 5 6
chain bonds :
1-9 2-23 3-22 4-7 5-21 6-20 7-8 7-18 7-19 9-10 10-27 11-12 11-24 24-26
24-25 24-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-8 24-26
exact bonds :
1-9 2-23 3-22 4-7 5-21 6-20 7-18 7-19 9-10 10-27 11-12 11-24 24-25
24-27

normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS
24:CLASS 25:CLASS
26:CLASS 27:CLASS

L9 STRUCTURE UPLOADED

=> d l9
L9 HAS NO ANSWERS
L9 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l9
SAMPLE SEARCH INITIATED 17:29:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    53341 TO ITERATE

  3.7% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      1053050 TO  1080590
PROJECTED ANSWERS:               0 TO        0

L10           0 SEA SSS SAM L9

=> s l9 ful
FULL SEARCH INITIATED 17:29:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  1054250 TO ITERATE

 94.9% PROCESSED  1000000 ITERATIONS                                3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.12

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      1054250 TO  1054250
PROJECTED ANSWERS:               3 TO        8
```

1/12/06

L11 3 SEA SSS FUL L9

=> d scan 1-3
'1-3' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

L11 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Guanidine, N-[(4S)-4-amino-5-[[4-(aminomethyl)phenyl]amino]pentyl]-N'-nitro- (9CI)
MF C13 H23 N7 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO

1/12/06

STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L11 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN L-Leucine, N2-[[4-(aminomethyl)phenyl]methyl]-L-lysyl-L-seryl-L-phenylalanyl-ψ(CH2-NH)- (9CI)
SQL 4
MF C32 H50 N6 O5

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



L11 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN L-Serinamide, N2-[[4-(aminomethyl)phenyl]methyl]-L-lysyl-N-[[4-[[[(1S)-1-carboxy-3-methylbutyl]amino]methyl]phenyl]methyl]- (9CI)
SQL 4

1/12/06

MF C31 H48 N6 O5

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NH_2

ALL ANSWERS HAVE BEEN SCANNED

10810649

1/12/06

```
=> d l1
L1 HAS NO ANSWERS
L1                STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=>  s l1
SAMPLE SEARCH INITIATED 14:40:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1731 TO ITERATE

100.0% PROCESSED     1731 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.05

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        32125 TO    37115
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 14:41:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    34394 TO ITERATE

100.0% PROCESSED    34394 ITERATIONS                                3 ANSWERS
```

1/12/06

SEARCH TIME: 00.00.01

L3 3 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 166.94 167.15

FILE 'CAPLUS' ENTERED AT 14:41:09 ON 12 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Jan 2006 VOL 144 ISS 3
FILE LAST UPDATED: 11 Jan 2006 (20060111/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 2 L3

=> d abs fbib hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I



II

AB Novel polyamines, their synthesis and use in pharmacol., cosmetic or agricultural applications are provided. Novel polyamines having the

structure (I) [wherein, n = 0-8; the aminomethyl functionality can be ortho, meta or para substituted; R = H, Me, Et, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminooctyl, N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminooctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl, N-ethyl-8-aminooctyl; R1 = H, straight or branched C1-20 (un)saturated aliphatic, aliphatic amine (except for propylamine when R = H, n=1 and the aminomethyl functionality is para substituted), alicyclic group, single or multi-ring aromatic group, single or multi-ring aryl substituted aliphatic group, aliphatic-substituted single or multi-ring aromatic group, single or multi-ring heterocyclyl, single or multi-ring heterocyclic-substituted aliphatic, aliphatic-substituted aromatic group, halogenated forms thereof; wherein said polyamine is a non-sym. xylene] are prepared Also provided are the use of the polyamines in pharmacol., cosmetic or agricultural applications. The polyamines induce antizyme production which in turn down regulates both the production of polyamines by ornithine decarboxylase (ODC) and the transport of polyamines by its corresponding polyamine transporter. These compds. will preferably enter the cell independent of the polyamine transporter. As drugs, these compds. are used as fungal, bacterial, viral and parasitic agents or to treat any disease associated with cellular proliferation including cancer, mucositis, asthma, inflammation, autoimmune disease, psoriasis, restentosis, rheumatoid arthritis, scleroderma, systemic and cutaneous lupus erythematosus, Type I insulin dependent diabetes, tissue transplantation, osteoporosis, hyperparathyroidism, treatment of peptic ulcer, glaucoma, Alzheimer's disease, Crohn's disease, and other inflammatory bowel diseases. A series of compds. I were screened for their ability to induce frameshifting using the dual luciferase reporter assay in HEK-293 cells. Some of these compds. induced frameshifting substantially better than spermidine. For example, compound (II) showed the percent relative frameshifting value (% RF) of 150% compared to 25 μM spermidine.

AN 2004:878166 CAPLUS
DN 141:366226
TI Preparation of polyamine analogs that activate antizyme frameshifting
IN Burns, Mark R.; Graminski, Gerard F.
PA Mediquest Therapeutics, Inc., USA
SO U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 251,819.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004209926	A1	20041021	US 2004-810649	20040329
				US 2002-251819 A2	20020923
	US 2004058954	A1	20040325	US 2002-251819	20020923
	US 6914079	B2	20050705		

PATENT FAMILY INFORMATION:
FAN 2004:252193

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004058954	A1	20040325	US 2002-251819	20020923
	US 6914079	B2	20050705		
	US 2004209926	A1	20041021	US 2004-810649	20040329
				US 2002-251819 A2	20020923

WO 2005105729 A1 20051110 WO 2004-US9582 20040329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2002-251819 A 20020923

OS MARPAT 141:366226

IT **673461-33-1P**, 1-Aminomethyl-4-(10-amino-2,7-diazadecyl)benzene
778831-92-8P, 1-Aminomethyl-4-(11-amino-2,7-diazaundecyl)benzene
778831-98-4P, 1-Aminomethyl-4-(12-amino-2,7-diazadodecyl)benzene
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of polyamine analogs as activating agents for antizyme frameshifting to treat diseases associated with cellular proliferation or as antifungal, antibacterial, antiviral and antiparasitic agents)

RN 673461-33-1 CAPLUS
CN 1,4-Benzenedimethanamine, N-[4-[(3-aminopropyl)amino]butyl]- (9CI) (CA INDEX NAME)



RN 778831-92-8 CAPLUS
CN 1,4-Benzenedimethanamine, N-[4-[(4-aminobutyl)amino]butyl]- (9CI) (CA INDEX NAME)



RN 778831-98-4 CAPLUS
CN 1,4-Benzenedimethanamine, N-[4-[(5-aminopentyl)amino]butyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

AB The invention provides synthesis and use of polyamines in pharmacol., cosmetic or agricultural applications. The polyamines induce antizyme production which in turn down regulates both the production of polyamines by ornithine decarboxylase (ODC) and the transport of polyamines by its corresponding polyamine transporter. These compds. will preferably enter the cell independent of the polyamine transporter. As drugs, these compds. are used to treat any disease associated with cellular proliferation including but not limited to cancer. As such, they will be useful as drugs to treat diseases where components of the immune system undergo undesired proliferation. The compds. will also be effective for the treatment of unwanted proliferation of hair or skin. The invention also identifies key structural elements expected to comprise the antizyme inducing motifs of small mols. related to polyamines.

AN 2004:252193 CAPLUS
DN 140:264534

TI Polyamine analogs that activate antizyme framshifting

IN Burns, Mark R.; Graminski, Gerard F.
PA Mediquest Therapeutics, Inc., USA

SO U.S. Pat. Appl. Publ., 29 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004058954	A1	20040325	US 2002-251819	20020923
	US 6914079	B2	20050705		
	US 2004209926	A1	20041021	US 2004-810649	20040329
				US 2002-251819 A2	20020923
	WO 2005105729	A1	20051110	WO 2004-US9582	20040329

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002-251819 A 20020923

PATENT FAMILY INFORMATION:

FAN 2004:878166

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004209926	A1	20041021	US 2004-810649	20040329
				US 2002-251819 A2	20020923
	US 2004058954	A1	20040325	US 2002-251819	20020923
	US 6914079	B2	20050705		

OS MARPAT 140:264534

IT **673461-33-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polyamine analogs that activate antizyme framshifting)

1/12/06

RN 673461-33-1 CAPLUS
CN 1,4-Benzenedimethanamine, N-[4-[(3-aminopropyl)amino]butyl]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.68	191.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.50	-1.50

STN INTERNATIONAL LOGOFF AT 14:42:23 ON 12 JAN 2006

Connecting via Winsock to STN